Article Text

Download PDFPDF
Novel treatment (new drug/intervention; established drug/procedure in new situation)
Observations and hypothesis on an individual patient topically treated for capecitabine-induced Palmar-Plantar syndrome
  1. Arie R Gafson1,
  2. Olivia Goodkin1,
  3. Richard Begent2
  1. 1UCL, London, UK
  2. 2Department of Oncology, UCL Cancer Institute, London, UK
  1. Correspondence to Arie R Gafson, arie.gafson.09{at}ucl.ac.uk

Summary

Palmar-Plantar syndrome (PPS) is a common side effect of oral capecitabine—a chemotherapeutic agent used as an adjuvant treatment for colorectal cancer. A 66-year-old man suffering from grade II PPS described how Germolene New Skin, a topical healing agent, provided relief from the pain associated with this syndrome and a return to normal function. The patient's observations form the basis for some interesting hypotheses regarding the natural progression of PPS and the potential of New Skin to alleviate pain. Caution must be exercised at this stage as these are single case observations; however, they may be worthy of further exploration in a randomised controlled clinical trial.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • ARG and OG are joint first authors.

  • Competing interests None.

  • Patient consent Obtained.